Bliss GVS Pharma shares were in sharp focus on Monday morning, rising around 7% at 9:30 am after Anupam Rasayan announced a plan to acquire a substantial stake in the company. The transaction, valued at about Rs 1,369 crore, has triggered strong market interest as investors assess the implications of a possible change in ownership and control. The stock’s move shows how quickly the market is reacting to strategic deal-related developments in the pharma space.
The proposed acquisition has been structured in a way that could give Anupam Rasayan a controlling position in Bliss GVS Pharma over time. As per the details, the deal includes a large stake purchase at a fixed price, along with an open offer for public shareholders. That has added to speculation that the transaction may eventually reshape the company’s strategic direction and long-term business priorities.
At around 9:30 am, Bliss GVS Pharma was trading at Rs 309.0, up Rs 8.65 or 2.88% on the NSE, with the stock moving between a day low of Rs 305.7 and a day high of Rs 324.9. The move came as investors reacted to the acquisition announcement and the possibility of a mandatory open offer for public shareholders.
According to the disclosure, Anupam Rasayan will acquire a 43.3% stake in Bliss GVS Pharma at Rs 299 per share, amounting to Rs 1,369.51 crore, and will also launch an open offer for an additional 26% stake from public shareholders at the same price. The transaction may eventually take the total holding up to 74.2%, including an optional further purchase of remaining shares.
Disclaimer: This article is generated for informational purposes only and does not constitute financial, investment, or trading advice. The data and analysis presented are based on publicly available market information at the time of writing. Markets are subject to risk. Please consult a qualified financial advisor before making any investment or trading decisions. Business Upturn does not accept responsibility for any losses arising from reliance on this content.